Feed CLNN
CL

Clene Inc.

CLNN · NASDAQ

$3.57 -4.03% (-$0.15)
1M -14.80%
Market Cap $51.0M
P/E Ratio -
Div. Yield -
ROE -
Piotroski F-Score Weak
2/9
Valuation
0 /100
Expensive
P/S 259.13x
P/E N/A
P/FFO N/A
Growth
0 /100
Declining
Rev. growth 24.94%
EPS growth N/A
Book val. growth N/A
Profitability
0 /100
Weak
Gross margin 110.15%
FCF margin 8,103.50%
Net margin 20,059.90%
Quality
0 /100
Poor
ROIC 104.55%
Asset turnover 0.01x
ROA 171.51%
Debt
43 /100
Moderate
Current ratio 3.07x
Int. coverage -10.15x
Debt/Equity N/A
Stability
24 /100
Unstable
Beta 0.95x
Profitable years 0
Rev. volatility 47.95%

Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe

Întreabă StockBot despre CLNN
Online

Despre companie

Clene Inc. (CLNN) is a biotechnology company focusing on the development and commercialization of therapeutic therapies based on nanotechnologies for the treatment of neurodegenerative diseases. The company concentrates on developing therapeutic products that utilize nanocrystalline platforms to support nerve cell recovery and protection from degeneration. Clene Inc. is engaged in addressing diseases like amyotrophic lateral sclerosis (ALS) and other neurodegenerative disorders. With the growing awareness of the need for neurodegenerative disease treatment, Clene Inc. has the potential for sustained growth. Clene Inc. (CLNN) shares might be an interesting choice for investors seeking involvement in the biotechnology and therapeutic therapies for neurodegenerative diseases.

Nu este încă disponibil în limba dumneavoastră, așa că textul este în engleză.

Sector

Healthcare

Industry

Biotechnology

CEO

Robert Etherington

Employees

78

Headquarters

Salt Lake City

Evenimente viitoare

12 NOV.

Earnings

Upcoming earnings report

61d

Folosim cookie-uri esențiale pentru funcționarea site-ului și cookie-uri analitice opționale pentru a măsura utilizarea. Consultați Politica de confidențialitate.